Jim Simons Protagonist Therapeutics, Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 144,167 shares of PTGX stock, worth $6.46 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

144,167

Previous 297,467 51.54%

Holding current value

$6.46 Million

Previous $10.3 Million 37.15%

% of portfolio

0.01%

Previous 0.02%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$33.72 - $47.33 $5.17 Million - $7.26 Million	-153,300 Reduced 51.54%	144,167 $6.48 Million
Q2 2024 Aug 09, 2024	BUY	$24.66 - $34.8 $6.53 Million - $9.22 Million	264,900 Added 813.4%	297,467 $10.3 Million
Q1 2024 May 13, 2024	SELL	$21.79 - $32.15 $3.95 Million - $5.83 Million	-181,400 Reduced 84.78%	32,567 $942,000
Q4 2023 Feb 13, 2024	SELL	$14.05 - $23.44 $172,829 - $288,335	-12,301 Reduced 5.44%	213,967 $4.91 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $2.74 Million - $3.88 Million	-163,999 Reduced 42.02%	226,268 $3.77 Million
Q2 2023 Aug 11, 2023	SELL	$18.02 - $29.36 $5.42 Million - $8.83 Million	-300,600 Reduced 43.51%	390,267 $10.8 Million
Q1 2023 May 12, 2023	BUY	$10.78 - $25.38 $4.66 Million - $11 Million	432,000 Added 166.88%	690,867 $15.9 Million
Q4 2022 Feb 13, 2023	SELL	$7.36 - $11.17 $1.04 Million - $1.57 Million	-140,900 Reduced 35.25%	258,867 $2.82 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $604,434 - $900,499	76,900 Added 23.82%	399,767 $3.37 Million
Q2 2022 Aug 12, 2022	BUY	$7.06 - $25.52 $2.14 Million - $7.74 Million	303,400 Added 1558.53%	322,867 $2.55 Million
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $454,359 - $702,369	19,467 New	19,467 $461,000
Q1 2021 May 13, 2021	SELL	$19.02 - $31.15 $680,858 - $1.12 Million	-35,797 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$18.49 - $25.13 $5.56 Million - $7.56 Million	-300,903 Reduced 89.37%	35,797 $722,000
Q3 2020 Nov 13, 2020	SELL	$15.19 - $22.4 $2.97 Million - $4.38 Million	-195,600 Reduced 36.75%	336,700 $6.58 Million
Q2 2020 Aug 13, 2020	SELL	$6.19 - $18.84 $266,789 - $812,004	-43,100 Reduced 7.49%	532,300 $9.4 Million
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $230,709 - $393,915	-42,724 Reduced 6.91%	575,400 $4.06 Million
Q4 2019 Feb 13, 2020	BUY	$4.69 - $13.45 $295,582 - $847,672	63,024 Added 11.35%	618,124 $4.36 Million
Q3 2019 Nov 13, 2019	BUY	$9.41 - $16.56 $402,748 - $708,768	42,800 Added 8.35%	555,100 $6.67 Million
Q2 2019 Aug 12, 2019	BUY	$8.98 - $12.96 $963,554 - $1.39 Million	107,300 Added 26.49%	512,300 $6.2 Million
Q1 2019 May 14, 2019	BUY	$6.5 - $13.77 $423,800 - $897,804	65,200 Added 19.19%	405,000 $5.09 Million
Q4 2018 Feb 13, 2019	BUY	$6.3 - $10.44 $2.14 Million - $3.55 Million	339,800 New	339,800 $2.29 Million

Others Institutions Holding PTGX

# of Institutions

247

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account